Item 7.01 Regulation FD Disclosure.

Aquestive Therapeutics, Inc. (the "Company") is furnishing the investor presentation attached as Exhibit 99.1 to this report for use at the Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum on Monday, December 9, 2019 at the American Epilepsy Society (AES) 2019 Annual Meeting. This investor presentation references the clinical data found in poster presentations conducted at that meeting which will be posted to the Company's website (under "Newsroom" and "Presentations") at the time of each presentation.

The Company also has been notified that a pre-IND meeting has been scheduled for February 4, 2020 with CDER of the US Food and Drug Administration to discuss AQST-108's clinical development strategy.

The information in this Item 7.01 (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.




Item 8.01 Other Events.

The Company was named as a defendant in a lawsuit filed by Neurelis, Inc. in the Superior Court of California on December 5, 2019. The complaint alleges, among other things, that the Company has made false and disparaging statements about Neurelis' product candidate, Valtoco, and engaged in other activities to delay potential FDA approval of Valtoco. The complaint seeks injunctive relief and unspecified monetary damages plus attorneys' fees. The Company believes these claims to be meritless and the Company intends to vigorously defend this lawsuit.

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits





        (d) Exhibits

Exhibit    Description
Number
           Investor presentation for use at the Investor & Analyst Libervant™
  99.1     (diazepam) Buccal Film Update Forum on Monday, December 9, 2019 at the
           American Epilepsy Society (AES) 2019 Annual Meeting

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses